| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05212025 Details | 2022-06-14 Interventional | 2 | 0 | Adavosertib Gemcitabine Pancreatic Neop… Pancreatic Canc… | manufacturer choice - | |||
| NCT04780581 2020-005026-28 Details | 2022-06-14 Interventional | 4 | 127 | Dexamethasone Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Coronavirus Inf… Infections Corona Virus In… | Impossibility of reaching the sample size established by protocol - | |||
| NCT04173338 Details | 2022-06-14 Interventional | 1 | 9 | Pemetrexed Carcinoma, Non-… Lung Neoplasms Mesothelioma Mesothelioma, M… Malignant Mesot… Non Small Cell … Non-squamous No… Urothelial Carc… | Closed by IRB on 3/28/22 - | |||
| NCT04173325 Details | 2022-06-14 Interventional | 1 | 10 | Irinotecan Nivolumab Lung Neoplasms Small Cell Lung… Small-cell Lung… | Closed by the IRB 5/26/22 due to non-compliance - | |||
| NCT03219164 2016-002749-42 Details | 2022-06-14 Interventional | 3 | 149 | Aztreonam Communicable Di… Cystic Fibrosis Fibrosis Infections Pseudomonas Inf… Respiratory Tra… Pseudomonas Aer… | Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus
disease 2019 (COVID-19) pandemic. The study was terminated early due to Coronavirus disease 2019 (COVID-19) pandemic. At the time of study termination, all evaluable participants completed the initial eradication period and provided data for the primary analysis. | |||
| NCT03091491 Details | 2022-06-14 Interventional | 2 | 31 | Ipilimumab Nivolumab Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of
alternative therapy and clinician's choice to put patient on immunotherapy outside of trial
setting. - | |||
| NCT04829799 Details | 2022-06-13 Interventional | 4 | 0 | Ketorolac Lidocaine Oxymetazoline Phenylephrine Pain Reduction | Per study team, the study will not proceed - | |||
| NCT03259425 Details | 2022-06-13 Interventional | 2 | 7 | Nivolumab Melanoma | DSMC Recommendation - | |||
| NCT04636034 Details | 2022-06-10 Interventional | 3 | 18 | Anesthetics Anesthetics, Lo… COVID-19 Ganglion Cysts Headache Synovial Cyst Covid19 Persistent Head… Sphenopalatine … | Recruitment failure - | |||
| NCT02900560 Details | 2022-06-10 Interventional | 2 | 34 | Azacitidine Cc-486 Pembrolizumab Carcinoma, Ovar… Ovarian Neoplas… Epithelial Ovar… | - Trial closed prematurely with 34 participant enrolled in Part A of the study. All of the treatment cohorts met at least one of the safety rejection criteria. Enrollment took 31 months, significantly longer than anticipated (24 months). | |||
| NCT02514447 2016-004611-13 Details | 2022-06-09 Interventional | 1/2 | [1 Refs] | 123 | Topotecan Lung Neoplasms Small Cell Lung… Small Cell Lung… | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety
concerns. Limitation of the trial is small numbers of subjects, since it is a Phase 2 clinical trial. Small sample size may have reduced the ability to observe statistically significant treatment effects on secondary myelopreservation measures (i.e. occurrence of FN AEs, infections and antibiotics usage). | ||
| NCT03970694 Details | 2022-06-08 Interventional | 3 | 49 | Capecitabine Oxaliplatin Colonic Neoplas… Colon Cancer | Significant differences in conversion rate as well as R0 resection rate between the two groups. - | |||
| NCT04994561 Details | 2022-06-07 Interventional | 1 | 0 | Dasatinib Metformin Niacinamide Quercetin Resveratrol Aging | Study was withdrawn - | |||
| NCT04836832 Details | 2022-06-07 Interventional | 1 | 0 | Acalabrutinib Tyrosine Kinase… Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Non-H… Recurrence Recurrent Folli… Recurrent Margi… Recurrent Nodal… Recurrent Splen… Refractory Foll… Refractory Indo… Refractory Marg… Refractory Noda… Refractory Sple… | PI decision - | |||
| NCT04420299 2020-001548-24 Details | 2022-06-07 Interventional | 2 | 81 | Bemiparin Heparin, Low-Mo… COVID-19 Covid-19 | Lack of funding of the non-commercial sponsor to extend recruitment and reach the target number
of patients specified in the protocol. - | |||
| NCT03077698 Details | 2022-06-07 Interventional | 2 | 25 | 10-carboxymethy… Megestrol Megestrol Aceta… Progestins Endometrial Neo… Endometrial Can… | The study was discontinued due to a change in development strategy and not due safety concern. The study was discontinued early due to a change in development strategy and not due safety concern. No safety concerns were noted during the trial. This change in development strategy was the determining factor in the decision to discontinue the study. Because the study was terminated early, the planned analysis was not conducted, as full enrollment was not met. | |||
| NCT02644525 Details | 2022-06-07 Interventional | 2 | 20 | Imatinib Mesyla… Loiasis | Planned interim analysis demonstrated futility of intervention - | |||
| NCT04049266 Details | 2022-06-06 Interventional | 2/3 | 558 | Aflibercept Macular Degener… Wet Macular Deg… | Primary Endpoint Not Met - | |||
| NCT03865615 Details | 2022-06-06 Interventional | 2 | 0 | Oxytocin Alcoholism Alcohol Use Dis… | COVID made study visits impossible during the funding period. - | |||
| NCT02374424 Details | 2022-06-06 Interventional | 2 | 29 | Obinutuzumab Lymphoma Lymphoma, Large… Diffuse, Large … | Interim analysis planned as per protocol didn't provide positive outcome therefore enrollment
was not reopened. However, the enrolled patients concluded therapy and continued into the
follow-up phase. The study was closed only after LVLP. - |